FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer

Open Access

Peer-reviewed

Research Article

Junmei Hou,

Affiliation Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Liewei Wang

* E-mail: wang.liewei@mayo.edu

Affiliation Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America
⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Pancreatic cancer
Is the Subject Area "Pancreatic cancer" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
AKT signaling cascade
Is the Subject Area "AKT signaling cascade" applicable to this article?

Thanks for your feedback.
Small interfering RNA
Is the Subject Area "Small interfering RNA" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.